GlassScriptPhysician profile
Charles T Shaw
NPI 1720086960
$1,598.59
in general payments reported to CMS, 2019-2025
25 companies · $60.06 in 2025
The $60.06 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $498 · 2021: $439 · 2022: $283 · 2023: $137 · 2025: $60.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.53 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $208.20 | 2019-2023 | |
| Amgen INC. | $136.17 | 2019-2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.17 | 2020-2021 | |
| Lilly USA, LLC | $107.45 | 2020-2022 | |
| Esperion Therapeutics, INC. | $95.54 | 2020-2021 | |
| Amarin Pharma, INC. | $94.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $74.03 | 2020-2025 | Arexvy, Shingrix |
| Seqirus USA INC | $72.57 | 2019-2022 | |
| Sanofi Pasteur INC. | $40.89 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.31 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.19 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.46 | 2020 | |
| Agile Therapeutics, INC. | $23.78 | 2021 | |
| Abbott Laboratories | $23.09 | 2023 | Proclaim |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.93 | 2021 | |
| Almatica Pharma LLC | $21.82 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.49 | 2023 | Keveyis |
| E.R. Squibb & Sons, L.L.C. | $20.03 | 2021 | |
| Exact Sciences Corporation | $19.90 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $19.90 | 2020 | |
| Hikma Pharmaceuticals USA | $16.74 | 2019 | |
| Roche Diabetes Care, INC. | $15.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.